Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir

Predictive Factors of the Treatment Failure in HCV Mono-infected Patients Treated With Pegylated-interferon/Ribavirin/Telaprevir.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01577069

Acronym

GENUPI

Enrollment

Registered

2012-04-13

Start date

2011-02-28

Completion date

2013-01-31

Last updated

2016-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Keywords

Hepatitis C, Direct Antiviral agent (DAA), Ultra-deep pyrosequencing, Single polynucleotide polymorphisms, Treatment-resistant mutants, Hepatitis C Virus Protease Inhibitor

Brief summary

The purpose of the study is to 1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after Telaprevir treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HCV mono-infected subjects * Age \> 18 years

Exclusion criteria

* HBV co-infection

Design outcomes

Primary

Measure	Time frame
virological resitance	12 weeks after treatment

Countries

France

Outcome results